-
2025-523094-42-00
5
Hirschsprung's disease
-
2025-523285-25-00
5
Relapsed or Refractory Multiple Myeloma
-
2025-523521-18-00
5
Metastatic Colorectal Cancer
-
2025-523544-12-00
5
Myelodysplastic neoplasms/syndromes (MDS)
-
2025-523555-66-00
5
Myelofibrosis
-
2025-523735-19-00
5
Metastatic Microsatellite Stable Colorectal Cancer
-
2025-523895-22-00
4
Non-small cell lung cancer (NSCLC)
-
2025-524408-30-01
5
Metastatic hormone-sensitive prostate cancer
-
2024-516527-13-00
11
2026-05-27
Kidney transplantation
-
2025-522007-18-00
5
2026-05-27
Relapsed or Refractory Multiple Myeloma
-
2025-522093-36-00
10
2026-05-20
Cancer cachexia
-
2024-511496-14-00
5
2026-05-14
Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
-
2025-523104-71-00
5
2026-05-08
Obesity or Overweight Without Type 2 Diabetes
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-523234-66-00
4
2026-04-17
Well-Controlled Recurrent Pericarditis
-
2025-520675-86-00
4
2026-03-10
Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Li
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2023-508056-19-00
5
2025-10-02
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
-
2024-516646-19-00
5
2025-08-15
Type 2 diabetic patients with no prior cardiovascular (CV) events
-
2024-516233-12-00
3
2025-08-08
Advanced pancreatic adenocarcinoma